Member Info for 1DayRodney

In this company's short lifetime , the management seems to have raised a bit of a sleeping lion - golden goose chimera.
There's a fair way to go yet before we can reap the full rewards of all these dealings, but it's definitely getting interesting :)

I thought the inference from the last presentation was that the proceeds were to be used towards the purchase of the Sonara royalty if the court case judgement is favourable (?)

Just a reminder that TRR are presenting their 'Q4 results and operational developments' via the Investor Meet Company platform this afternoon at 2pm uk time.

Gheko said
"Just a thought…..circa 630,000 babies born each year in UK and circa 3.6 MILLION in US alone.

That’s a lot of tests worth a lot of money and then our stroke test. Circa 100,000 strokes each year in UK and circa 800,000 in US."

The birth figures are a bit misleading. The difference being not every baby needs to take the test, only those that are ill.

Whereas the stroke test could potentially be used for all those who present with stroke symptoms or are to be given stroke medication as an emergency preventive action.

@ Nissan

Yet another 'price I'd be happy with'!!!?

I think this is the link you need....
https://www.metoffice.gov.uk/weather/forecast/uk

It'll tell you which way the wind's blowing today. Lol :)

What makes you think they would consider selling the royalty so early?
It's a high ROI and lucrative royalty in a mine with a 40yr life and for one of the most in demand commodities and now LAC also has a take off agreement with GM.
Don't forget there is already a 'buy back' in place for part of the royalty. The $55m/yr quoted is for after that buy back (if it takes place).
The name of the game with TRR is diversified royalty collection. Personally I would have thought they would've run with it for a few years before any thought of selling on.

This is why the FDA approval and USA market for AIHL assay are so important to Genedrive. Both would be transformational in both earnings and company growth.

" In 2021, 3.7 million babies were born in the US, with 10.5% born prematurely.
It was estimated that malpractice litigation settlements in cases related to deafness caused by the use of aminoglycosides averaged more than $1.1m per case, further adding to the positive health economic case of providing accurate and timely testing to reduce unwanted side effects of gentamicin usage."

That's $1.1m per case that could be effectively assured against by offering a test which the hospital would still charge for.
So it's a win-win for the hospital/medical schemes.

Full article here..

https://www.sharecast.com/amp/news/aim-bulletin/genedrive-engages-with-us-fda-over-infant-test--10905468.html

But this market would probably be dwarfed by a similar qualification for the Stroke assay.

Interesting times for GDR indeed...

The interesting thing about the Covid entry requirements the Italians have put into place is that testing is to be done on arrival and any positives are to be gene sequenced.
This is not the the simple 'LFT test before you fly'.
It would be interesting to see what Spain's full requirements will be and if they'll be similar as we do already have a distributor there.
I doubt we'll see anything from it but it's worth keeping an eye on.

Another little point I'd like to highlight is the repeated fact that we 'did not sell anything in the pandemic'. We should remember that during the pandemic we only had our PCR test for sale, which was indeed a massive flop. However our POC product was not available until last spring when the original pandemic had largely passed.
There still may be a small market for the POC Covid device, afterall, the original pandemic started 3yrs ago and it still haunts us.

I think the largest mistake we made was not to concentrate fully on the POC during the original pandemic rather than branching off into individual tests and the distraction of FDA approval. That and bad/misleading comms from the BOD. The POC device would probably have been available far sooner to the market and we wouldn't have wasted so much cash on PCR. After all, this company is all about the fantastic and versatile Genedrive device and that's what we would should've stuck to.

The original NICE scope as laid out in June 15th documentation was :

"The NICE diagnostics assessment programme will assess the clinical and cost-effectiveness of the Genedrive MT-RNR1 ID System (and any other alternative technologies identified during scoping) to make recommendations on its use in the NHS."

Subsequently the time scheduling was revised by moving the study onto the EVA path as stated in the scope document of Sept 20th:

"Following scoping of the topic it was decided that the topic should be assessed using the NICE early value assessment approach. This allows the NICE diagnostics advisory committee to consider the technology more quickly, and outline further data needed, potentially alongside use of the test in the NHS. "

The original scope i.e. to determine guidance of use within the NHS, has not changed. The only thing that has changed is the timetabling and methodology. Saves everybody's time and will potentially shorten the implementation of a technology that has already been extensively trialled within and hand-hand with the NHS.

So I'm curious as to why the 'legality' and gravity of the decision expected to be announced round the end of Feb is being queried?

in this 'ol town but rollin' tumbleweed and the sound of the wind....

BTW don't forget all the figures mentioned are up to June this year . They gave no indication either way about current sales figures, but from the mention of possible fund raising, we assume they are flat.

@jamrock

What the company are currently doing was explained in Monday's presentation.

Pdf copy of slides here:

http://www.genedriveplc.com/investor-relations/company-reports.php

Full video including Q&A can be found here:

https://www.investormeetcompany.com/

(registration required)

Basically AIHL is currently the main play.

For those who are interested, the NICE progress and documentation for the AIHL assay can be found here -

https://www.nice.org.uk/guidance/indevelopment/gid-dg10057

And for the stroke assay here -

https://www.nice.org.uk/guidance/indevelopment/gid-dg10054

The AIHL assay is on the 'fast track' EVA route for 'best practice' having completed all trials etc.

As I understand it from the documentation, the Stroke assay is still on the standard path because the product is still on trial/final development with Genedrive and the NHS, so could be switched to EVA/Best Practice route in Q1-23.

If both assays end up as 'Best Practice' then the company should be on the real path to growth and a bright future (or a take over target).

But I'm sure we'll get a more thorough update (good or bad) during Monday's presentation.

For those who are interested, you can register at

https://www.investormeetcompany.com/

to watch the 21st Nov presentation.
There is also an option to register any questions you would like to pose
- Might be the ideal time to hear it from the horse rather than the constant toing & froing speculation pedalled here.

"BOOOOOOM!!!"....

A bit tongue-in-cheek Mr Guy ?....lol

Re: Genedrive MT-RNR1

This is the ITV news report first broadcast in April (when the kit was officially launched).

https://youtu.be/eELuv69pRnk

It may be helpful for those who are recent investors, potential investors or for those who just plain missed it and want a bit more insight.
The report gives a good overview of it's operation and potential impact within the NHS (and hopefully further afield).

Interesting quote at the end of the article Tweeted by Genedrive recently..

https://www.entandaudiologynews.com/features/audiology-features/post/rapid-genetic-testing-to-avoid-hearing-loss-in-neonates

"Rollout throughout neonatal units across the NHS is under advanced discussion with commissioning teams, and we envisage that this test will be available to all at-risk babies in the next two years."

https://www.lithiumamericas.com/news/lithium-americas-confirms-oral-hearing-schedule-for-the-thacker-pass-record-of-decision-appeal

Don't think anyone (aside from the judge) knows for definite. The silence and delay is the sort of thing that may spook some investors - not just here but those who hold shares in LAC directly too.
I'm not saying it's at all linked, but there were some fairly chunky sales this morning.
Fingers crossed - let's hope the judgement is what we're looking for and soon!

NICE expect to publish their findings/recommendations 16th August '23

https://www.nice.org.uk/guidance/indevelopment/gid-dg10054